Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Watson

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Pharmacoeconomics|September 28, 2006
Anticoagulation for stroke prevention: high effectiveness, more cost benefit?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Journal of the American College of Cardiology|February 20, 2007
Endothelial progenitor cells in cardiovascular disordersEduard Shantsila, Timothy Watson, Gregory Y H Lip
International Journal of Cardiology|October 24, 2006
Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillationTimothy Watson, Eduard Shantsila, Gregory Y H Lip
International Journal of Cardiology|October 18, 2012
Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral veinTimothy Watson, Jan S Burd, Peter N Ruygrok
Thrombosis Research|May 20, 2008
Statins and inflammation: reciprocal effectors to endothelial progenitors?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Thrombosis Research|October 3, 2006
Aspirin resistance: what, why and when?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Current Opinion in Investigational Drugs (London, England : 2000)|April 6, 2007
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor XPuneet Kakar, Timothy Watson, Gregory Y H Lip
Clinical Medicine (London, England)|March 14, 2007
Modern management of atrial fibrillationTimothy Watson, Eduard Shanstila, Gregory Y H Lip
Drugs of Today (Barcelona, Spain : 1998)|March 24, 2007
RivaroxabanPuneet Kakar, Timothy Watson, Gregory Y H Lip
The American Journal of Cardiology|May 29, 2007
Cardioversion for atrial fibrillation: does inflammation matter?Timothy Watson, Puneet Kakar, Gregory Y H Lip
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Pharmacoeconomics|September 28, 2006
Anticoagulation for stroke prevention: high effectiveness, more cost benefit?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Journal of the American College of Cardiology|February 20, 2007
Endothelial progenitor cells in cardiovascular disordersEduard Shantsila, Timothy Watson, Gregory Y H Lip
International Journal of Cardiology|October 24, 2006
Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillationTimothy Watson, Eduard Shantsila, Gregory Y H Lip
International Journal of Cardiology|October 18, 2012
Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral veinTimothy Watson, Jan S Burd, Peter N Ruygrok
Thrombosis Research|May 20, 2008
Statins and inflammation: reciprocal effectors to endothelial progenitors?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Thrombosis Research|October 3, 2006
Aspirin resistance: what, why and when?Eduard Shantsila, Timothy Watson, Gregory Y H Lip
Current Opinion in Investigational Drugs (London, England : 2000)|April 6, 2007
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor XPuneet Kakar, Timothy Watson, Gregory Y H Lip
Clinical Medicine (London, England)|March 14, 2007
Modern management of atrial fibrillationTimothy Watson, Eduard Shanstila, Gregory Y H Lip
Drugs of Today (Barcelona, Spain : 1998)|March 24, 2007
RivaroxabanPuneet Kakar, Timothy Watson, Gregory Y H Lip
The American Journal of Cardiology|May 29, 2007
Cardioversion for atrial fibrillation: does inflammation matter?Timothy Watson, Puneet Kakar, Gregory Y H Lip
Pageof 8